{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:22:39Z","timestamp":1760782959653},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.diagmicrobio.2007.01.020","type":"journal-article","created":{"date-parts":[[2007,4,6]],"date-time":"2007-04-06T11:59:52Z","timestamp":1175860792000},"page":"9-17","source":"Crossref","is-referenced-by-count":17,"title":["Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values"],"prefix":"10.1016","volume":"58","author":[{"given":"Ronald N.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Fritsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew G.","family":"Stilwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2004.07.008","article-title":"Bactericidal activity of garenoxacin tested by kill-curve methodology against wild type and QRDR mutant strains of Streptococcus pneumoniae","volume":"50","author":"Anderegg","year":"2004","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0732-8893(03)00039-7","article-title":"Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzae and Streptococcus pneumoniae","volume":"46","author":"Anderegg","year":"2003","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"Suppl 1","key":"10.1016\/j.diagmicrobio.2007.01.020_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg212","article-title":"Development of the quinolones","volume":"51","author":"Andersson","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib4","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1128\/AAC.47.12.3935-3941.2003","article-title":"Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jac\/dkg110","article-title":"Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects","volume":"51","author":"Andrews","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib6","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1469-0691.2006.01387.x","article-title":"The effect of implementing the British Thoracic Society community-acquired pneumonia guidelines on antibiotic prescribing and costs in a UK teaching hospital","volume":"12","author":"Barlow","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0732-8893(03)00016-6","article-title":"Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program","volume":"46","author":"Biedenbach","year":"2003","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib8","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1086\/498119","article-title":"Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival","volume":"41","author":"Bodi","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM199907223410403","article-title":"Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network","volume":"341","author":"Chen","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib10","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard","article-title":"M7-A7","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib11","series-title":"Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement","article-title":"M100-S16","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib12","series-title":"Performance Standards for Antimicrobial Susceptibility Testing, 17th Informational Supplement","article-title":"M100-S17","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2007"},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib13","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1128\/JCM.00456-06","article-title":"Contemporary prevalence of BRO \u03b2-lactamases in Moraxella catarrhalis: report from the SENTRY Antimicrobial Surveillance Program (North America, 1997 to 2004)","volume":"44","author":"Deshpande","year":"2006","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib15","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1128\/AAC.49.12.5024-5032.2005","article-title":"In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program","volume":"49","author":"Draghi","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ijantimicag.2006.09.002","article-title":"Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003\u20132004)","volume":"28","author":"Draghi","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib16","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/jac\/48.5.667","article-title":"BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs","volume":"48","author":"Edelstein","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib17","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1378\/chest.125.5.1888","article-title":"Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia","volume":"125","author":"File","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib18","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/jac\/48.5.735-a","article-title":"Activity of the novel des-fluoro(6) quinolone BMS-284756 against methicillin-susceptible and -resistant staphylococci","volume":"48","author":"Fung-Tomc","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib19","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1128\/AAC.44.12.3351-3356.2000","article-title":"Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756","volume":"44","author":"Fung-Tomc","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1592\/phco.22.3.160.33556","article-title":"Effect of a high-fat meal on the pharmacokinetics of the des-F(6)-quinolone BMS-284756","volume":"22","author":"Gajjar","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib20","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1128\/AAC.47.7.2256-2263.2003","article-title":"Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects","volume":"47","author":"Gajjar","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/107662902760190617","article-title":"Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae","volume":"8","author":"Gillespie","year":"2002","journal-title":"Microb. Drug Resist."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/107662903764736300","article-title":"Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation","volume":"9","author":"Gillespie","year":"2003","journal-title":"Microb. Drug Resist."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib24","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1128\/JCM.41.8.3967-3969.2003","article-title":"Commercial broth microdilution panel validation and reproducibility trials for garenoxacin (BMS-284756), a novel desfluoroquinolone","volume":"41","author":"Gordon","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib25","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1179\/joc.2005.17.5.484","article-title":"Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens","volume":"17","author":"Hansen","year":"2005","journal-title":"J. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib26","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/00365540500264050","article-title":"Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults","volume":"37","author":"Hedlund","year":"2005","journal-title":"Scand. J. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib27","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1128\/AAC.45.2.589-592.2001","article-title":"Comparative antianaerobic activity of BMS 284756","volume":"45","author":"Hoellman","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib28","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1128\/AAC.46.11.3370-3380.2002","article-title":"Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone","volume":"46","author":"Ince","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0732-8893(03)00002-6","article-title":"Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999\u20132001)","volume":"45","author":"Jones","year":"2003","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0732-8893(00)00233-9","article-title":"Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci","volume":"39","author":"Jones","year":"2001","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib31","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1128\/AAC.46.10.3320-3322.2002","article-title":"Effects of the Des-F(6)-quinolone garenoxacin (BMS-284756), in comparison to those of ciprofloxacin and ofloxacin, on joint cartilage in immature rats","volume":"46","author":"Kappel","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib32","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1128\/AAC.49.6.2479-2486.2005","article-title":"Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of parC topoisomerase IV and gyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates","volume":"49","author":"Korzheva","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib33","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1128\/AAC.48.11.4460-4462.2004","article-title":"Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin","volume":"48","author":"Li","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib34","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/jac\/dkg017","article-title":"Impact of AUC\/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones","volume":"51","author":"Lister","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib35","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1128\/AAC.46.2.517-518.2002","article-title":"In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae","volume":"46","author":"Malay","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.otohns.2005.12.021","article-title":"Acute bacterial rhinosinusitis: a review of U.S. treatment guidelines","volume":"135","author":"Marple","year":"2006","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib37","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.200411-1444OC","article-title":"Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome","volume":"172","author":"Menendez","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2169\/internalmedicine.45.1691","article-title":"The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations","volume":"45","author":"Miyashita","year":"2006","journal-title":"Intern. Med."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib39","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1128\/AAC.47.5.1630-1635.2003","article-title":"Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model","volume":"47","author":"Nicolau","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib40","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1469-0691.2005.01286.x","article-title":"Predicted effects on antibiotic use following the introduction of British or North American guidelines for community-acquired pneumonia in The Netherlands","volume":"11","author":"Oosterheert","year":"2005","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib41","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1128\/AAC.40.10.2321","article-title":"Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae","volume":"40","author":"Pan","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib42","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1128\/AAC.41.5.1166","article-title":"Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae","volume":"41","author":"Perichon","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib43","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3201\/eid1209.051400","article-title":"Fluoroquinolone-resistant Streptococcus pneumoniae","volume":"12","author":"Pletz","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib44","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1183\/09031936.05.00102105","article-title":"Guidelines for the diagnoses and treatment of adult lower respiratory tract infections: a true \u201cEuropean cooperative effort\u201d","volume":"26","author":"Restrepo","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0732-8893(01)00247-4","article-title":"Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.","volume":"40","author":"Rhomberg","year":"2001","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib46","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1097\/01.CCM.0000147443.38234.D2","article-title":"Validation of the 2001 American Thoracic Society criteria for severe community-acquired pneumonia","volume":"32","author":"Riley","year":"2004","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1128\/AAC.47.1.211-215.2003","article-title":"Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci","volume":"47","author":"Rodriguez-Cerrato","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib48","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1469-0691.2001.0310b.x","article-title":"Antimicrobial activity of BMS 284756, a novel des-fluoro (6) quinolone and seven fluoroquinolones against Streptococcus pneumoniae","volume":"7","author":"Saravolatz","year":"2001","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib49","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jac\/49.4.698","article-title":"In vitro activity of the novel des-F(6) quinolone BMS-284756 against genetically characterized clinical streptococcal isolates, including isolates with reduced quinolone susceptibility","volume":"49","author":"Schmitz","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib50","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1128\/AAC.43.5.1077","article-title":"In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone","volume":"43","author":"Takahata","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib51","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1128\/AAC.45.1.312-315.2001","article-title":"In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae","volume":"45","author":"Takahata","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/jac\/dkf081","article-title":"In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates","volume":"50","author":"Valera","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib53","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1128\/AAC.48.12.4766-4777.2004","article-title":"Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections","volume":"48","author":"Van Wart","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib54","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/AAC.47.1.161-165.2003","article-title":"In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas","volume":"47","author":"Waites","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib55","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1128\/AAC.45.12.3517-3523.2001","article-title":"Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae","volume":"45","author":"Weigel","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/jac\/49.1.177","article-title":"The in vitro activity of BMS-284756, a new des-fluorinated quinolone","volume":"49","author":"Weller","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib57","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1128\/AAC.46.1.242-244.2002","article-title":"Single-dose pharmacokinetics and penetration of BMS 284756 into an inflammatory exudate","volume":"46","author":"Wise","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib58","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1128\/AAC.45.12.3660-3662.2001","article-title":"Mechanism of action of the des-F(6) quinolone BMS-284756 measured by supercoiling inhibition and cleavable complex assays","volume":"45","author":"Wu","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib60","article-title":"BMS-284756 demonstrates potent activity against Canadian lower respiratory tract infection pathogens isolated in 1999\u20132001, Abstr E711","author":"Zhanel","year":"2001"},{"key":"10.1016\/j.diagmicrobio.2007.01.020_bib59","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/jac\/dkl159","article-title":"Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae","volume":"58","author":"Zhanel","year":"2006","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889307000569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889307000569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T01:36:19Z","timestamp":1556328979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889307000569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0732889307000569"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2007.01.020","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}